Ocular immunology and inflammation · 2026
Pembrolizumab Associated Bilateral Optic Neuritis.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Finley Robert, Jeyaseelan Praveen
Аннотация
PURPOSE: To report a rare vision threatening side effect of pembrolizumab managed effectively by plasmapheresis.Method: Case report.
RESULTS: A 52-year-old female on Pembrolizumab for vulvar squamous cell carcinoma developed bilateral optic neuritis due to an altered immune system secondary to pembrolizumab targeting her nervous system.
CONCLUSION: Though brain metastasis and paraneoplastic optic neuropathy are feared complications in cancer patients with vision loss, drug induced bilateral optic neuropathy is a rare possibility and should be considered. As immune checkpoint inhibitors continue to grow in popularity and are approved for more uses, it is important for vigilant monitoring of immune-related adverse events (irAEs) as well as quick and effective management of these adverse reactions. Our patient did not respond to intravenous steroids and subsequent plasmapheresis helped good visual recovery.
RESULTS: A 52-year-old female on Pembrolizumab for vulvar squamous cell carcinoma developed bilateral optic neuritis due to an altered immune system secondary to pembrolizumab targeting her nervous system.
CONCLUSION: Though brain metastasis and paraneoplastic optic neuropathy are feared complications in cancer patients with vision loss, drug induced bilateral optic neuropathy is a rare possibility and should be considered. As immune checkpoint inhibitors continue to grow in popularity and are approved for more uses, it is important for vigilant monitoring of immune-related adverse events (irAEs) as well as quick and effective management of these adverse reactions. Our patient did not respond to intravenous steroids and subsequent plasmapheresis helped good visual recovery.